Your Health, We Care
Concomitant use with a strong or moderate CYP3A inhibitor and/or a P-gp inhibitor increases pralsetinib exposure, which may increase the risk of adverse reactions related to Pralsetinib. Avoid coadministration of Pralsetinib with a strong or moderate CYP3A and/or P-gp inhibitor. If coadministration with any of the above inhibitors cannot be avoided, reduce the Pralsetinib dose.
Concomitant use with a strong CYP3A inducer decreases pralsetinib exposure, which may decrease efficacy of Pralsetinib. Avoid concomitant use of Pralsetinib with strong or moderate CYP3A inducers. If coadministration of Pralsetinib with strong or moderate CYP3A inducers cannot be avoided, increase the Pralsetinib dose.
from FDA，2024.03
